11/21/2024

Janusmed kön och genus

Janusmed kön och genus – prednisolonnatriumsuccinat

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
B B
B B

Prednisolon – lokalt

Prednisolon – lokalt

Klass : B

Visa all info

Skriv ut

Kontakta oss

  1. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107-21.

  2. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]

  1. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107-21.
  2. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]
A A
A A

Prednisolon – systemiskt

Prednisolon – systemiskt

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777-87.

  2. Donnan PT, Libby G, Boyter AC, Thompson P. The population risk of fractures attributable to oral corticosteroids. Pharmacoepidemiol Drug Saf. 2005;14:177-86.

  3. Hansen KE, Kleker B, Safdar N, Bartels CM. A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children. Semin Arthritis Rheum. 2014;44:47-54.

  4. Magee MH, Blum RA, Lates CD, Jusko WJ. Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol. 2001;41:1180-94.

  5. Meffin PJ, Brooks PM, Sallustio BC. Alterations in prednisolone disposition as a result of time of administration, gender and dose. Br J Clin Pharmacol. 1984;17:395-404.

  6. Noureen N, Rana MT. Clinical profile and response to oral prednisolone in infantile spasm. J Coll Physicians Surg Pak. 2010;20:186-9.

  7. Hiraoka M, Tsukahara H, Haruki S, Hayashi S, Takeda N, Miyagawa K et al. Older boys benefit from higher initial prednisolone therapy for nephrotic syndrome The West Japan Cooperative Study of Kidney Disease in Children. Kidney Int. 2000;58:1247-52.

  8. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax. 2003;58:654-8.

  9. Greene AK, Couto RA. Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol. Plast Reconstr Surg. 2011;128:743-52.

  10. Morin C, Fardet L. Systemic glucocorticoid therapy: risk factors for reported adverse events and beliefs about the drug A cross-sectional online survey of 820 patients. Clin Rheumatol. 2015;34:2119-26.

  11. Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab. 2005;90:5234-40.

  12. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2017-01-26.]

  1. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777-87.
  2. Donnan PT, Libby G, Boyter AC, Thompson P. The population risk of fractures attributable to oral corticosteroids. Pharmacoepidemiol Drug Saf. 2005;14:177-86.
  3. Hansen KE, Kleker B, Safdar N, Bartels CM. A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children. Semin Arthritis Rheum. 2014;44:47-54.
  4. Magee MH, Blum RA, Lates CD, Jusko WJ. Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol. 2001;41:1180-94.
  5. Meffin PJ, Brooks PM, Sallustio BC. Alterations in prednisolone disposition as a result of time of administration, gender and dose. Br J Clin Pharmacol. 1984;17:395-404.
  6. Noureen N, Rana MT. Clinical profile and response to oral prednisolone in infantile spasm. J Coll Physicians Surg Pak. 2010;20:186-9.
  7. Hiraoka M, Tsukahara H, Haruki S, Hayashi S, Takeda N, Miyagawa K et al. Older boys benefit from higher initial prednisolone therapy for nephrotic syndrome The West Japan Cooperative Study of Kidney Disease in Children. Kidney Int. 2000;58:1247-52.
  8. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax. 2003;58:654-8.
  9. Greene AK, Couto RA. Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol. Plast Reconstr Surg. 2011;128:743-52.
  10. Morin C, Fardet L. Systemic glucocorticoid therapy: risk factors for reported adverse events and beliefs about the drug A cross-sectional online survey of 820 patients. Clin Rheumatol. 2015;34:2119-26.
  11. Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab. 2005;90:5234-40.
  12. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2017-01-26.]